CCL14 (C-C motif chemokine ligand 14) is a chemotactic cytokine that functions as both an anti-microbial peptide and inflammatory mediator with significant clinical relevance. The protein exhibits weak chemotactic activity on monocytes at high concentrations (100-1000 nM), inducing intracellular calcium changes and enzyme release without promoting chemotaxis 1. Its processed form HCC-1(9-74) demonstrates enhanced chemotactic properties, attracting monocytes, eosinophils, and T-cells through binding to CCR1, CCR3, and CCR5 receptors 1. CCL14 has emerged as a highly valuable biomarker for predicting persistent acute kidney injury (AKI), particularly sepsis-associated AKI, with superior diagnostic performance compared to other biomarkers (AUC 0.79-0.85) across different patient populations including ICU, sepsis, and post-operative settings 2. The protein also demonstrates prognostic value in hepatocellular carcinoma, where it serves as a driver gene influencing patient survival and disease recurrence 3. In cardiovascular disease, CCL14 is expressed by pro-inflammatory endothelial cells and linked to cardiac fibrosis development 4. Additionally, CCL14 shows distinct expression patterns in pancreatic acinar-specific endothelial cells, suggesting specialized roles in pancreatic vascular biology and potential involvement in diabetes pathophysiology 5.